Northern Trust’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-250,118
| Closed | -$43M | – | 4831 |
|
|
2021
Q3 | $43M | Sell |
250,118
-10,085
| -4% | -$1.32M | 0.01% | 1203 |
|
|
2021
Q2 | $32.7M | Buy |
260,203
+170
| +0.1% | +$21.4K | 0.01% | 1526 |
|
|
2021
Q1 | $35.3M | Buy |
260,033
+4,407
| +2% | +$569K | 0.01% | 1405 |
|
|
2020
Q4 | $32.7M | Sell |
255,626
-411
| -0.2% | -$48.2K | 0.01% | 1418 |
|
|
2020
Q3 | $28.8M | Buy |
256,037
+15,719
| +7% | +$1.56M | 0.01% | 1330 |
|
|
2020
Q2 | $22.9M | Sell |
240,318
-348,754
| -59% | -$33.6M | 0.01% | 1501 |
|
|
2020
Q1 | $52.9M | Buy |
589,072
+3,218
| +0.5% | +$250K | 0.02% | 745 |
|
|
2019
Q4 | $31.1M | Buy |
585,854
+25,942
| +5% | +$1.18M | 0.01% | 1380 |
|
|
2019
Q3 | $22.1M | Buy |
559,912
+30,930
| +6% | +$1.34M | 0.01% | 1609 |
|
|
2019
Q2 | $21.7M | Buy |
528,982
+9,636
| +2% | +$399K | 0.01% | 1629 |
|
|
2019
Q1 | $24.2M | Buy |
519,346
+58,729
| +13% | +$2.58M | 0.01% | 1524 |
|
|
2018
Q4 | $20.1M | Sell |
460,617
-4,063
| -0.9% | -$203K | 0.01% | 1581 |
|
|
2018
Q3 | $26.6M | Buy |
464,680
+11,622
| +3% | +$571K | 0.01% | 1550 |
|
|
2018
Q2 | $22M | Buy |
453,058
+15,661
| +4% | +$571K | 0.01% | 1716 |
|
|
2018
Q1 | $17.1M | Buy |
437,397
+371
| +0.1% | +$15.8K | ﹤0.01% | 1802 |
|
|
2017
Q4 | $18.5M | Buy |
437,026
+56,109
| +15% | +$2.1M | ﹤0.01% | 1766 |
|
|
2017
Q3 | $14.2M | Sell |
380,917
-453
| -0.1% | -$15.7K | ﹤0.01% | 1969 |
|
|
2017
Q2 | $11.6M | Buy |
381,370
+43,891
| +13% | +$1.27M | ﹤0.01% | 2066 |
|
|
2017
Q1 | $8.93M | Buy |
337,479
+5,716
| +2% | +$151K | ﹤0.01% | 2193 |
|
|
2016
Q4 | $8.47M | Buy |
331,763
+17,967
| +6% | +$569K | ﹤0.01% | 2221 |
|
|
2016
Q3 | $11.4M | Sell |
313,796
-1,194
| -0.4% | -$39.6K | ﹤0.01% | 1975 |
|
|
2016
Q2 | $10.7M | Buy |
314,990
+26,701
| +9% | +$868K | ﹤0.01% | 1981 |
|
|
2016
Q1 | $7.61M | Buy |
288,289
+35,763
| +14% | +$1.04M | ﹤0.01% | 2155 |
|
|
2015
Q4 | $12.3M | Buy |
252,526
+11,607
| +5% | +$418K | ﹤0.01% | 1855 |
|
|
2015
Q3 | $6M | Buy |
240,919
+65,665
| +37% | +$1.97M | ﹤0.01% | 2335 |
|
|
2015
Q2 | $5.54M | Buy |
175,254
+11,296
| +7% | +$365K | ﹤0.01% | 2451 |
|
|
2015
Q1 | $6.24M | Sell |
163,958
-835
| -0.5% | -$33.2K | ﹤0.01% | 2371 |
|
|
2014
Q4 | $6.42M | Sell |
164,793
-1,867
| -1% | -$65.1K | ﹤0.01% | 2337 |
|
|
2014
Q3 | $5.04M | Buy |
166,660
+65,699
| +65% | +$1.85M | ﹤0.01% | 2506 |
|
|
2014
Q2 | $3.43M | Buy |
100,961
+14,346
| +17% | +$480K | ﹤0.01% | 2773 |
|
|
2014
Q1 | $2.99M | Sell |
86,615
-707
| -0.8% | -$31.9K | ﹤0.01% | 2887 |
|
|
2013
Q4 | $3.46M | Buy |
+87,322
| New | +$2.11M | ﹤0.01% | 2804 |
|
Northern Trust's XLRN Position: Q4 2021 in Review
Northern Trust sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 250,118 shares — an estimated $43M sold.
Northern Trust first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $52.9M in Q1 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Northern Trust reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Northern Trust sold 250,118 Acceleron Pharma shares in Q4 2021, an estimated $43M.
- Northern Trust first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
- Northern Trust's Acceleron Pharma position peaked at $52.9M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Northern Trust's 13F filing for Q4 2021, filed 8 Feb 2022.